# Monitoring of Brain Metabolites Using Proton and Deuterium MR Techniques

Study · id `cardio:ct-nct06705010` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06705010](<https://clinicaltrials.gov/study/NCT06705010>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06705010

Browse, organ or system: Blood vessels; Brain; Metabolism  
Browse, condition area: Stroke; Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 140 participants.

## Technical summary

Registry record NCT06705010. Non-randomized; single masking; primary purpose basic science. Start 2025-04-01 (anticipated); primary completion 2026-11-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; single masking; primary purpose basic science
- Phase: Not applicable
- Enrolled: 140 participants (planned count; ClinicalTrials.gov record NCT06705010, source copy `cardio:ctgov-nct06705010-2025-03-25`, retrieved 2026-10-26)
- Planned start: 2025-04-01 (anticipated) (ClinicalTrials.gov record NCT06705010, source copy `cardio:ctgov-nct06705010-2025-03-25`, retrieved 2026-10-26)
- Primary completion: 2026-11-01 (anticipated) (ClinicalTrials.gov record NCT06705010, source copy `cardio:ctgov-nct06705010-2025-03-25`, retrieved 2026-10-26)
- Completion: 2028-03-31 (anticipated) (ClinicalTrials.gov record NCT06705010, source copy `cardio:ctgov-nct06705010-2025-03-25`, retrieved 2026-10-26)
- Countries: Switzerland (ClinicalTrials.gov record NCT06705010, source copy `cardio:ctgov-nct06705010-2025-03-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06705010-2025-03-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Monitoring of Brain Metabolites Using Proton and Deuterium MR Techniques
- Acronym: SIGNATURES2023
- Condition: Aging
- Condition: Brain Metabolic Disorder
- Condition: Carotid Stenosis
- Condition: Alzheimer Disease
- Condition: Diabetes Type 2
- Condition: Mild Cognitive Impairment
- Condition: Brain Disease
- Intervention (Device): Application of new pulse sequence package SIGNATURES2023 to healthy controls
- Intervention (Device): Application of new pulse sequence package SIGNATURES2023 to 4 groups of patients (pilot)
- Lead sponsor: Insel Gruppe AG, University Hospital Bern
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Carotid artery stenosis (`cardio:carotid-stenosis`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Insel Gruppe AG, University Hospital Bern (`cardio:org-insel-gruppe-ag-university-hospital-bern`)

## Provenance

Content hash: 06fb1d32626d5d4d2cad3e97dce3f42a706b755f30d3672771687c1635e9986d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
